Volume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
00:00
00:00
00:00
 

Chapters

Transcript

 

ULKA VAISHAMPAYAN: So monotherapy responses in the Part B section of ARTISTRY-1-- this was a study conducted in advanced melanoma and advanced kidney cancer. Here we found that patients-- actually six out of the 46 patients had a partial response, of which six were mucosal melanoma patients. And of these, two had a partial response. These were all patients who had failed prior immune checkpoint therapy. So that makes these response even more significant, given that these were pretreated patients who had shown resistance or at least progressed post-immune checkpoint therapy.

All responders had been on this therapy and progressed. And there were-- the responses were-- not only were their responses seen, but they tended to be durable. There is one mucosal melanoma patient that is continuing at more than six months on therapy and duration of response in weeks. The median was 16.7 weeks. In the mucosal melanoma, there is a-- median response was about 78 weeks, so more than a year response was noted with the mucosal melanoma patient. And because of that there is an orphan status-- orphan FDA status has been designated for nemvaleukin in mucosal melanoma.

Along with that, the other cohort in renal cell carcinoma, 22 patients were enrolled. And of those, partial response was noted in four patients. Again, these partial responses were very durable. Median duration of response in weeks is 15.6 weeks. And there is one patient that has gone as long as 63 weeks on therapy.

So clinically meaningful responses were observed in metastatic kidney cancer, also with IV nemvaleukin therapy. And all of these patients, all of these responders also had been on prior checkpoint inhibitor therapy and had shown signs of progression prior to enrollment on nemvaleukin therapy.

Video

Can you drill down into the results for Part B of the ARTISTRY-1 study and share results in terms of partial and/or complete responses observed in different tumor subtypes, including mucosal melanoma, advanced kidney cancer, and ovarian carcinoma?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

Ulka Vaishampayan, MBBS

Ulka Vaishampayan, MBBS

Professor of Internal MedicineDirector, Phase I ProgramRogel Cancer CenterUniversity of MichiganAnn Arbor, MI